Paul Fernyhough
Degrees, Title/Position:
BSc PhD
Professor and Acting Head- Department of Pharmacology and Therapeutics
Professor Department of Physiology , University of Manitoba Director of Division of Neurodegenerative Disorders, St. Boniface Research Centre
Goal Groups/Integration Themes:
Clinical Trials & New Therapies
Description:
There is no FDA-approved treatment for diabetic neuropathy, a condition that afflicts half of the 27 million North Americans who suffer from diabetes. The neurodegeneration seen in diabetes leads to sensory fiber depletion and loss of protective sensation – a primary trigger of the diabetic foot and lower limb amputation. With financial support from several key stakeholders in the field of diabetes, a small start-up company, WinSanTor Inc, was established in 2012 and is developing a proprietary first-in-class therapy to prevent and reverse nerve damage. The SPOR network will perform phase 2 clinical trials with novel topical therapeutics provided by WinSanTor.
PubMed Link:
Home Page/Departmental Page:
Dr. Paul Fernyhough, Neurodegeneration Lab | St. Boniface Hospital Research